Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics.
FEATURED CONTENT
An EDC Option You Didn’t Know You Had!
Signant Health offers the most comprehensive eClinical suite in life sciences, now featuring a recently acquired EDC/DDC solution proven in more than 3,000 clinical trials over 25+ years. Sponsors and CROs are switching to Signant Health's EDC for its ease of use, efficiency, flexibility, and superior support. Plus, study teams can choose a full-service or self-service model to accommodate the needs of any trial or program.
CLINICAL TRIAL OPTIMIZATION
Signant’s comprehensive, end-to-end clinical trial optimization solutions are fully supported by more than fifty full-time clinicians, scientists, medical practitioners, and key opinion leaders experienced in all therapeutic areas. In addition to reliable, proven solutions and scientific expertise, sponsors and CROs leverage Signant’s global scale and trial delivery expertise. Our approach to trial optimization is to ensure the best practices and best solutions are in place to help your programs succeed. Explore these resources to learn more about how this approach ensures trials generate reliable, accurate, submission-ready data.
RESOURCES & PERSPECTIVES
-
![GettyImages-1314299046 econsent]( "Comparative Effectiveness Of eConsent: Systematic Review")
Comparative Effectiveness Of eConsent: Systematic ReviewThis blog post examines eConsent vs. ICF on comprehension, acceptability, enrollment, retention, consent time, and site workload.
-
![GettyImages-1160240937 smartphone]( "Exploring The Potential Of Non-Consumer Smartphones In Clinical Trials")
Exploring The Potential Of Non-Consumer Smartphones In Clinical TrialsWe selected and evaluated a non-consumer device, to explore its potential as a reliable tool for home-based ePRO measure administration. Here’s what we learned from this usability testing.
-
![Heart-Attack-heart-disease-GettyImages-1359314170]( "Measuring Aspects Of Health In Heart Failure Research")
Measuring Aspects Of Health In Heart Failure ResearchDr. Bill Byrom sat with Cardiology Professor Marianna Fontana to discuss opportunities for measuring aspects of health meaningful for increasing the usefulness of COA measures in heart failure trials.
-
![signant pediatric thumb]( "Recap – Optimizing Pediatric Trials To Generate High-Quality Data")
Recap – Optimizing Pediatric Trials To Generate High-Quality DataIn pediatric trials, leading pediatric clinical research expert Dr. Joan Busner explains that age and cognitive differences make COA measurement more complex and harder to standardize.
-
![Doctor-Patient-Question-Network]( "Increasing The Usefulness Of PROs In Oncology Research")
Increasing The Usefulness Of PROs In Oncology ResearchDr. Anthony Everhart (Clinical VP, Internal Medicine, Signant Health) and Tim Meyer (Professor, Experimental Cancer Medicine, University College London) discuss opportunities for increasing the usefulness of PROMs.
SUCCESS STORIES
-
![GettyImages-980809416 clinical supply]( "Consolidating Clinical Supply Chain Operations With GxP Inventory")
Consolidating Clinical Supply Chain Operations With GxP InventoryA Japan-based biotechnology company leveraged Signant SmartSignals® GxP Inventory, which improved visibility, reduced risks and costs, and optimized operations in this case study.
-
![GettyImages-1693748594 phone]( "RTSM: Randomization And Cohort Management, IP Inventory Management")
RTSM: Randomization And Cohort Management, IP Inventory ManagementSignant’s SmartSignals® RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.
-
![GettyImages-1359760465 doctor ipad]( "Unified Platform Supports Rapid Implementation Of Rescue Study")
Unified Platform Supports Rapid Implementation Of Rescue StudyExplore how these integrated solutions helped an emerging biopharma to implement a plan for study build and migration with minimal disruption to sites.
-
![Covid-vaccine-GettyImages-1325017357]( "eSource For A COVID Treatment Trial")
eSource For A COVID Treatment TrialUnearth how this emerging biopharmaceutical company was able to overcome challenges to successfully facilitate a Phase 2 trial for a COVID-19 treatment in critically ill patients.
-
![GettyImages-1184502868 oncology patient]( "Emerging Biopharm Rapidly Sets Up Phase 1 Oncology Trial")
Emerging Biopharm Rapidly Sets Up Phase 1 Oncology TrialUncover how an emerging biopharmaceutical company was able to expedite the initiation of a Phase 1 oncology trial for a novel treatment targeting relapsed/refractory multiple myeloma.
CONTACT INFORMATION
Signant Health
785 Arbor Way
Blue Bell, PA 19422
UNITED STATES
Phone: 610.400.4141
EVIDENCE GENERATION
IP MANAGEMENT
APPLICATIONS & THERAPEUTIC AREAS
VIDEOS & WEBINARS
If you missed Signant’s webinar about optimizing patient-reported outcomes measurement strategy throughout oncology drug development, we’ve summarized the key takeaways and provided the recording.
In this segment from Clinical Leader's Solutions Expo: EDC Showcase, Jan Breemans, Senior Director of Global Solutions at Signant Health, presents novel applications for EDC in modern trial designs.
Industry experts discuss how EDC solutions address nuances in modern trial designs such as flexible assessment settings as well as assist modern working practices for study monitors and data managers.